The purpose of this study is to test the feasibility and preliminary efficacy of a novel electronic decision aid to improve AML patients' understanding of their illness, prognosis, and treatment options.

The purpose of this study is to test the feasibility and preliminary efficacy of a novel electronic decision aid to improve AML patients' understanding of their illness, prognosis, and treatment options. The objective of our program of research is to ultimately improve understanding about what patients with Acute Myeloid Leukemia (AML) know and understand about their disease, as well as what kind of information AML patients want or need to further inform them about the treatment decisions they face.

The AML Decision Aid tool consists of ten video modules, approximately 3 minutes each, containing content regarding key areas such as an explanation of what AML is, treatment choices, and things to consider when determining a treatment path. Recruited subjects will complete a series of surveys, both before viewing of the videos and after

Inclusion Criteria:

• At least age 18

• Capacity to give consent

• Diagnosis of acute myeloid leukemia (AML)

• Fluent in English

• Receiving care at Duke, and fits into one of the following scenarios:

  • has not yet made a treatment decision (in the DCI clinics or on the inpatient wards),
  • have recently made a decision (in the last 6 weeks), and are admitted for chemotherapy on 9100 or in the oncology treatment center to receive outpatient therapy,
  • or, during remission, while receiving consolidation chemotherapy in the hospital

Exclusion Criteria:

• Patients too sick to participate per clinician discretion